"Since its introduction in the late 1980s, HIV antiretroviral therapy (ART) has saved millions of lives by transforming HIV from a fatal disease into a chronic, manageable condition. Despite these achievements, ART is not a cure, and even after decades of treatment, HIV will rebound rapidly in nearly all individuals who stop therapy. Lifelong ART is accompanied by numerous challenges, such as social stigma and fatigue associated with the need to take pills daily."
"The global economic burden of ART, particularly in low- and middle-income countries where HIV is most prevalent, adds to the urgency of finding alternatives. Two studies published in Nature by Kiani et al. and Peluso et al. represent signposts along this path, illuminating how antibody-based therapies might work with powerful cellular immune responses to allow HIV to be controlled without ART."
Antiretroviral therapy (ART) transformed HIV from a fatal disease into a chronic, manageable condition and has saved millions since the late 1980s. ART is not curative, and HIV typically rebounds rapidly when treatment is stopped, even after decades. Lifelong ART creates challenges including social stigma, pill fatigue, and significant economic burden, especially in low- and middle-income countries. T cells with stem-cell-like properties, when combined with antibody-based therapies, show potential to generate powerful cellular immune responses that could control HIV without continuous ART, offering a possible pathway toward durable remission.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]